Compare Lucid Group Inc (LCID) vs Novavax Inc (NVAX) Price & Performance

Lucid Group (LCID) trades at $3.82, down 1.8% on the day, with a bearish technical signal and weak fundamentals. The company reported a net loss of $2.70 billion in 2025, with negative gross and net income margins, and has missed earnings expectations for three consecutive quarters. Recent news highlights cost-saving initiatives and autonomous vehicle partnerships, but also delays in the Cosmos SUV launch and concerns over cash burn.

The outlook remains challenging due to persistent losses and high cash burn, though analyst consensus suggests potential upside with a $7.60 price target. Key risks include execution delays, competitive pressures, and the need for additional financing. Investor sentiment is cautious, with most analysts rating the stock Hold.

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.